NKF Spring Clinical Meetings 2024
Changes to the ordering plan could help optimize the use of SZC to treat acute hyperkalemia.
Nocturnal hypertension is common in CKD, but it was unclear if renal denervation could lower nighttime blood pressure.
A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.
Severe hyperkalemia after adrenalectomy is rare but can be managed medically with sodium zirconium cyclosilicate (SZC).
Sparsentan demonstrated meaningful benefits for preservation of kidney function compared with irbesartan over 2 years.
Dose adjustment requirements may differ between ESA-hyporesponsive and non–ESA-HR patients receiving daprodustat.
Pooja Desai discussed a study examining short- vs long-term results of SZC therapy on hyperkalemia-related hospitalization.
In patients with chronic kidney disease, higher serum concentrations were associated with slower CKD progression.
A retrospective study examined whether SGLT2is are associated with cardiorenal benefits for patients with type 1 diabetes.
Patients with chronic kidney disease (CKD) may lack awareness of medication options for managing hyperkalemia.
A roadmap created by the Kidney Health Initiative provides tangible ways to better address APOL1-mediated kidney disease.
Life-threatening hyperkalemia can be treated successfully with medical management instead of dialysis.
Two years after its approval, researchers studied the use of finerenone in adults with type 2 diabetes and CKD.
Results of the SPRINT study favored intensive blood pressure control in older adults.
Long- and short-term use of SZC were compared to assess their association with rates of hyperkalemia-related hospitalization.
A study examined gastrointestinal bleeding in patients with chronic kidney disease (CKD).
Dr. David Charytan shared his thoughts on his career and winning the NKF's J. Michael Lazarus Distinguished Award.
Researchers measured the prevalence and burden of patients whose chronic kidney disease (CKD) was not diagnosed.
A study evaluated renal outcomes of chlorthalidone versus hydrochlorothiazide in patients with hypertension.
The APPLAUSE-IgAN study evaluated iptacopan plus supportive care in patients with IgA nephropathy (IgAN).
The PROTECT trial evaluated sparsentan versus irbesartan for nephroprotection in IgA nephropathy (IgAN).
Researchers studied the relationship between CKD and serum urate by assessing stage prevalence after first gout diagnosis.
Nephrology Times will cover the National Kidney Foundation Spring Clinical Meetings 2024 live and onsite.
The National Kidney Foundation honored distinguished health care professionals at the 2024 Spring Clinical Meetings.
Advertisement
Advertisement
